A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator.

Trial Profile

A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Effects of Once-Daily Oral Doses of 75 mg Azimilide Dihydrochloride on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients with an Implantable Cardioverter Defibrillator.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Azimilide (Primary)
  • Indications Ventricular arrhythmias; Ventricular fibrillation; Ventricular tachycardia
  • Focus Registrational; Therapeutic Use
  • Acronyms SHIELD-2
  • Sponsors Forest Laboratories
  • Most Recent Events

    • 01 Mar 2017 Primary endpoint (Time to first cardiovascular event) has not been met, according to the results published in the American Heart Journal.
    • 01 Mar 2017 Results published in the American Heart Journal
    • 03 May 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top